Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Long-term results of the HOVON-84 randomized phase III study by the HOVON and the Nordic Lymphoma Group (clinical trial number: NTR1014)

IF 7.6 1区医学 Q1 ONCOLOGY

European Journal of Cancer Pub Date : 2024-11-22 DOI:10.1016/j.ejca.2024.115144

Pieternella Johanna Lugtenburg, Peter de Nully Brown, Bronno van der Holt, Eva de Jongh, Josée M. Zijlstra

引用次数: 0

查看原文本刊更多论文

弥漫性大b细胞淋巴瘤首次完全缓解患者的利妥昔单抗维持：HOVON和北欧淋巴瘤组进行的HOVON-84随机III期研究的长期结果（临床试验编号：NTR1014）

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Cancer 医学-肿瘤学

CiteScore

11.50

自引率

4.80%

发文量

953

审稿时长

23 days

期刊介绍： The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.